|REACTIVITY||H M R Mk Pg|
For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
From sample preparation to detection, the reagents you need for your Western Blot are now in one convenient kit: #12957 Western Blotting Application Solutions Kit
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 10
Human, Mouse, Rat, Monkey, Pig
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human BAG6 protein. Antibodies are purified by protein A and peptide affinity chromatography.
BAG6 (BCL2-associated athanogene-6), alternately known as BAT3 (HLA-B-associated transcript 3), was originally identified as a gene within the class III region of the human major histocompatibility complex, but has subsequently been found to exhibit protein chaperone activity. BAG6, in conjunction with other chaperone proteins and ubiquitin ligases, regulates protein stability and insertion of tail-anchored membrane proteins into the endoplasmic reticulum (1-3). The BAT3 complex, consisting of BAG6, TRC35 and Ubl4a localizes to ribosomes synthesizing membrane proteins and facilitates tailed-anchored protein capture by TRC40 and subsequent insertion of the nascent protein in to the ER membrane (4,5). BAG6 also plays a critical role in clearing cells of mis-folded and mis-localized peptides via endoplasmic reticulum-associated degradation and the ubiquitin-proteasome system (1,6,7). BAG6 may also act as a chaperone for glycoproteins through its interaction with DERLIN2 (8).
In addition to its role as a chaperone, BAG6 has also been implicated in regulating chromatin structure and gene expression. For example, BAG6 and SET1A act as binding partners for BORIS to effect changes of chromatin structure and gene expression (9). Similarly, increased expression of BAG6 induces p300-mediated acetylation of p53, which is required for DNA damage response (10). BAG6 has also been found to interact with TGF-β, and in so doing acts as a positive regulator of TGF-β1 stimulation of type 1 collagen expression (11). BAG6 also suppresses bone morphogenic protein (BMP) signaling via its interaction with and regulation of small C-terminal domain phosphatase (SCP) that dephosphorylates SMAD proteins resulting in subsequent termination of BMP-mediated events (12).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.